Menotas Xp 300 IU Prefilled Syringe 1

Menotas Xp 300 IU Prefilled Syringe 1 may interact with the following medicines:

• Other fertility medicines such as follitropin alfa or menotropins: Concurrent use may enhance ovarian stimulation and increase the risk of ovarian hyperstimulation syndrome (OHSS) in women undergoing fertility treatment.
• Gonadotropin-releasing hormone (GnRH) agonists or antagonists such as leuprolide or cetrorelix: Combined use may alter hormonal responses and requires careful monitoring during assisted reproductive procedures.
• Hormonal medicines such as progesterone or oestrogen preparations: Concurrent use may influence fertility treatment outcomes and should be used according to specialist recommendations.

Menotas Xp 300 IU Prefilled Syringe 1 may interact with diseases/conditions, including:

• Polycystic ovary syndrome (PCOS): Women with PCOS may have an increased risk of excessive ovarian response and ovarian hyperstimulation syndrome during treatment.
• Hormone-sensitive tumours: Patients with tumours of the pituitary gland, hypothalamus, ovaries, breasts, testes, or prostate should use this medicine only under specialist supervision.
• Ovarian cysts: Existing ovarian cysts may enlarge during treatment and require monitoring.
• Thromboembolic disorders: Patients with a history of blood clots may have an increased risk of thromboembolic events during fertility treatment.

The dose of Menotas Xp 300 IU Prefilled Syringe 1 should be administered exactly as prescribed by your doctor. The dosage and treatment schedule depend on the condition being treated, treatment response, and individual patient requirements.

An overdose of Menotas Xp 300 IU Prefilled Syringe 1 is unlikely to occur as it is administered by a healthcare professional.

If you miss a scheduled dose of Menotas Xp 300 IU Prefilled Syringe 1, contact your doctor or healthcare provider to reschedule the injection.